|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.04.25 - 01:48
|
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire EN)
|
|
|
CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days....
|
|
|
|
|
|
|
|
|
29.01.25 - 13:03
|
XORTX to Present at Microcap Conference (GlobeNewswire EN)
|
|
|
CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces attendance and presentation at the Microcap Conference hosted by DealFlow Events on January 28 through 30, 2025 in Atlantic City, NJ. Attendance at this conference continues outreach to the investment community and provides XORTX with an opportunity to update investors on our newly announced gout program. The presentation on January 29, 2025 will review the Company's plans to advance the XRx-026 program for gout through a New Drug Application (“NDA”) filing, and activities associated with the XRx-008 program for autosomal dominant polycystic kidney disease (“ADPKD”), including registration clinical trial preparations. ...
|
|
|
17.01.25 - 23:03
|
XORTX Announces Change of Auditor (GlobeNewswire EN)
|
|
|
CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the Company has changed its auditor from Smythe LLP, Chartered Professional Accountants (“Former Auditor”) to Davidson & Company LLP, Chartered Professional Accountants, (“Successor Auditor”) effective January 16, 2025....
|
|
|
|
|
|
|
19.12.24 - 13:06
|
XORTX stärkt sein Führungsteam (IRW Press)
|
|
|
- Dr. Michael Bumby kommt als Chief Financial Officer zu XORTX CALGARY, AB 19. Dezember 2024 / IRW-Press / XORTX Therapeutics Inc. (XORTX oder das Unternehmen) (NASDAQ: XRTX | TSXV: XRTX |......
|
|
|
|
|
|
|
12.12.24 - 15:21
|
XORTX Announces Presentation at the Rare and Genetic Disease Summit (GlobeNewswire EN)
|
|
|
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled “Autosomal Dominant Polycystic Kidney Disease - Genetic and Environmental Factors → Evidence for Aberrant Purine Metabolism as a Second Hit Determining Disease Progression.”...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
